Fierce Pharma

FEBRUARY 7, 2024

Despite markedly slower cell therapy growth from the third to the fourth quarter of 2023—and a recent setback for Trodelvy—historically HIV-focused Gilead Sciences is not discouraged amid its | Despite a tame level of fourth-quarter growth, recent advances should drive long-term cell therapy sustainability, Gilead execs said. Overall, the company is pushing to generate 30% of its revenues from oncology by 2030.

257

257

MedCity News

FEBRUARY 7, 2024

Strengthening health IT infrastructure is a critical and necessary step toward abating the opioid crisis and evaluating the impact of how opioid settlement dollars are allocated across communities.

Pharma 130

Pharma 130

Fierce Pharma

FEBRUARY 7, 2024

As part of the acquisition of manufacturing giant Catalent, Novo Nordisk will fork over $11 billion for three of the CDMO’s plants. | While Catalent’s Bloomington, Indiana, site is no stranger to FDA reprimands, its latest write-up is notable given that the site forms part of the $16.5 billion deal Novo Holdings struck to acquire Catalent earlier this week.

Manufacturing 247

Manufacturing FDA 247

MedCity News

FEBRUARY 7, 2024

Establishing site-neutral payments for outpatient services is a hot issue in Capitol Hill right now. Advocates say that such policy would lower healthcare costs, saving both patients and taxpayers money. Opponents say that it would put hospitals’ financial security at risk and jeopardize access to care.

Healthcare 119

Healthcare Healthcare Patients 119

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

FEBRUARY 7, 2024

Even with Leqembi now sporting a full FDA approval and benefiting from the simpler Medicare coverage that distinction brings, Eisai and Biogen’s latest Alzheimer’s disease med appears to be moving | While Japan’s Eisai had set the goal to reach 10,000 patients with Leqembi by the end of its 2024 fiscal year, which wraps up in March, only 2,000 patients in the U.S. were receiving the amyloid-busting antibody as of Jan. 26, Eisai explained in a third-quarter earnings presentation.

FDA 250

FDA Patients 250

European Pharmaceutical Review

FEBRUARY 7, 2024

AstraZeneca has announced a $300 million investment in a US-based manufacturing facility in Rockville, Maryland, which will focus initially on T-cell therapies for oncology indications. The site will launch the company’ s cell therapy platforms in the US for critical cancer trials and future commercial supply. The site may widen its focus to support other disease areas, according to AstraZeneca.

Manufacturing 103

Manufacturing Medicine Networking Patients 103

pharmaphorum

FEBRUARY 7, 2024

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into targeted cancer therapies. Under the terms of the deal, Jazz will acquire Redx’s KRAS inhibitor programme outright, including multiple preclinical-stage drug candidates, and will take responsibility for ushering the most promising compounds through clinical trials and onto the market.

Pharma 109

Pharma Pharmaceutical Marketing 109

Fierce Pharma

FEBRUARY 7, 2024

Despite reaching new heights in breast cancer, Eli Lilly’s Verzenio has been sent packing in prostate cancer. | Despite reaching new heights in breast cancer, Eli Lilly’s Verzenio has been sent packing in prostate cancer. Meanwhile, the Indianapolis pharma has another phase 3 prostate cancer program in the works.

Pharma 233

Pharma 233

European Pharmaceutical Review

FEBRUARY 7, 2024

A paper published in Biotechnology Progress has explored real-time deviation management for integrated continuous bioprocesses and highlighted the role of automation. The discussion was based on a case study produced by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). Specifically, the case study discussed a control strategy in the context of integrated continuous bioprocesses ( ICB ) for monoclonal antibodies (mAbs).

Management 97

Management Leads Manufacturing Pharmaceutical 97

Fierce Pharma

FEBRUARY 7, 2024

After Amgen completed its $27.8 billion buyout of Horizon Therapeutics in October, executives at the California biotech made it a priority to right the course of thyroid eye disease treatment Tepez | After Amgen completed its $27.8 billion buyout of Horizon Therapeutics in October, executives at the California biotech made it a priority to right the course of thyroid eye disease treatment Tepezza—an instant blockbuster that saw a perplexing slide in just its third full year on the market.

Sales 227

Sales Marketing 227

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

MedCity News

FEBRUARY 7, 2024

Gilead Sciences said an independent review of interim Phase 3 data found the immunotherapy, magrolimab, led to a higher risk of death. Though Gilead is discontinuing further development of the drug in blood cancers, a review is ongoing in solid tumors.

Safety 105

Safety Leads FDA Biopharma 105

Fierce Pharma

FEBRUARY 7, 2024

With an upfront payment of $100 million, Kyowa Kirin has bought into a partnership with BridgeBio to develop and commercialize infigratinib in Japan.

205

205

pharmaphorum

FEBRUARY 7, 2024

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there but was withdrawn from sale after it failed a confirmatory trial.

Sales 99

Sales Marketing 99

MedCity News

FEBRUARY 7, 2024

Providing patients with comprehensive patient resource sheets on clinical trials can alleviate worry, support dialog with family members and clinical care providers and empower informed decision-making.

Patients 99

Patients Healthcare Healthcare Education 99

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

Pharmaceutical Technology

FEBRUARY 7, 2024

AstraZeneca is investing $300m in a facility in Rockville, US - a significant step in launching its cell therapy platforms in the country.

97

97

MedCity News

FEBRUARY 7, 2024

Amazon has eliminated “a few hundred” jobs across Amazon Pharmacy and One Medical, the company confirmed to MedCity News Wednesday. While some may believe this could lead to Amazon leaving healthcare, one industry expert said that would be an “overly simplistic” takeaway.

Healthcare 98

Healthcare Healthcare Medical Leads 98

pharmaphorum

FEBRUARY 7, 2024

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings purchase of Catalent and the sale of three manufacturing facilities to Novo Nordisk.

Manufacturing 87

Manufacturing Sales 87

Pharmaceutical Technology

FEBRUARY 7, 2024

Gilead Sciences has announced a 22.9% increase in net income of $5.61bn for FY23 as against $4.56bn in FY22.

98

98

Advertisement

pharmaphorum

FEBRUARY 7, 2024

Jewish people in England are being asked to have gene testing for BRCA mutations that elevate their risk of breast cancer

103

103

PharmaTimes

FEBRUARY 7, 2024

The HTA reported that Brainomix 360 improved access to treatment for stroke patients

Patients 106

Patients 106

pharmaphorum

FEBRUARY 7, 2024

Life sciences communications agency Real Chemistry has more than doubled its medical team through the acquisition of Avant Healthcare. The takeover – which was completed earlier this month for an undisclosed sum – will bolster Real Chemistry’s medical education, medical affairs, and healthcare provider (HCP) communications capabilities, said the company in a statement.

Healthcare Provider 59

Healthcare Provider Education Medical Healthcare 59

PharmaTimes

FEBRUARY 7, 2024

The new products are in the areas of gastrointestinal and respiratory medicines

Medicine 90

Medicine 90

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Pharmaceutical Technology

FEBRUARY 7, 2024

Avadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma.

75

75

PharmaVoice

FEBRUARY 7, 2024

Investment heavyweights BlackRock and Glass Lewis want compensation clawbacks on execs who don’t protect a company’s reputation.

Pharma 65

Pharma 65

Pharmaceutical Technology

FEBRUARY 7, 2024

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).

Pharma 71

Pharma 71

PharmExec

FEBRUARY 7, 2024

Data from the ENHANCE-3 trial of magrolimab in combination with azacitidine plus Venclexta showed futility and an increased risk of death in patients with acute myeloid leukemia.

FDA 52

FDA Patients 52

Advertisement

Distribution

Pharmaceutical Technology

FEBRUARY 7, 2024

(Sacubitril + valsartan) is under clinical development by Novartis and currently in Phase II for Hypertrophic Cardiomyopathy.

74

74

Quantified

FEBRUARY 7, 2024

Traditional sales training is hitting a roadblock. It may still provide sound fundamental skills to sales agents new to the profession or your organization, but it’s not designed for a modern workforce or modern buyers requiring individualized approaches. It’s part of the reason why companies spend millions every year on sales training with varying levels of impact.

Training 52

Training Sales Sales Management Management 52

Pharmaceutical Commerce

FEBRUARY 7, 2024

Phase III CheckMate -77T trial data show statistically significant improvements in event-free survival with Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo in the treatment of resectable stage IIA to IIIB non-small cell lung cancer.

52

52

PharmExec

FEBRUARY 7, 2024

Results from the Phase III CheckMate -77T trial show that Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo produced statistically significant and clinically meaningful improvements in event-free survival in patients with resectable stage IIA to IIIB non-small cell lung cancer.

Patients 52

Patients 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales